# US 2006/0153937 A1 · Synergistic composition for the treatment of diabetes mellitus

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2006/0153937 A1
- Document ID: US20060153937A1
- Status: Published application
- Kind: A1
- Application number: 11/356,274
- Filed: 2006-02-15
- Published: 2006-07-13
- Earliest claimed: 2003-05-14
- Assignees: Indus Biotech Pvt. Ltd.
- Inventors: Sunil Bhaskaran; Vishwaraman Mohan
- Web page: https://patentgrep.com/patent/US20060153937A1

## CPC

- A61K 31/195: having an amino group
- A61K 31/198: Alpha-amino acids, e.g. alanine or edetic acid [EDTA] (betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00)
- A61K 31/205: Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
- A61K 31/56: Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K 36/48: Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 5/50: for increasing or potentiating the activity of insulin
- A61P 7/12: Antidiuretics, e.g. drugs for diabetes insipidus (ADH A61P5/10)
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to a synergistic composition for the treatment of diabetes in a subject in need thereof, said composition-comprising Trigonelline of concentration ranging between 20 to 30%, amino acids of concentration ranging between 20 to 60%, and soluble fiber of concentration ranging between 10 to 60%, optionally along with pharmaceutically acceptable additives, a process thereof and also, a method of treating diabetes.

## Claims

### Claim 1

A method of treating diabetes in a subject in need thereof, said method comprising step of administering pharmaceutically acceptable amount of composition comprising Trigonelline of concentration ranging between 20 to 30%, amino acids of concentration ranging between 20 to 60%, and soluble fiber of concentration ranging between 10 to 60%, optionally along with pharmaceutically acceptable additives, to the subject.

### Claim 2 (depends on 1)

A method of treating as claimed in claim 1, wherein the amino acids are selected from a group comprising L-arginine, Leucine, Isoleucine, and 4-Hydroxyisoleucine.

### Claim 3 (depends on 1)

A method of treating as claimed in claim 1, wherein the soluble fiber is galactomannan.

### Claim 4 (depends on 1)

A method of treating as claimed in claim 1, wherein the additives are extracted from the same fenugreek, which comprises of a group a containing galactomannan.

### Claim 5 (depends on 1)

A method of treating as claimed in claim 1, wherein the diabetes is type II diabetes.

### Claim 6 (depends on 1)

A method of treating as claimed in claim 1, wherein the composition is free of adverse effects.

### Claim 7 (depends on 1)

A method as claimed in claim 1, wherein the administration of the synergistic composition is at dosage ranging between 50 to 2000 mg/kg body weight.

### Claim 8 (depends on 1)

A method as claimed in claim 1, wherein the method shows hypoglycemic effect of about 51%.

### Claim 9 (depends on 1)

A method as claimed in claim 1, wherein the method shows about 300% increase in the viability of the islets.

### Claim 10 (depends on 1)

A method as claimed in claim 1, wherein the method maintains the morphology of the pancreatic cells.

### Claim 11 (depends on 1)

A method as claimed in claim 1, wherein the synergistic composition is administered orally.

### Claim 12 (depends on 1)

A method as claimed in claim 1, wherein the synergistic composition acts at the pancreas through potassium channel mediated insulin secretion.

### Claim 13

A method of treating diabetes in a subject in need thereof, said method-comprising step of administering pharmaceutically acceptable amount of Trigonelline, amino acids and galactomannan fibers, optionally along with pharmaceutically acceptable additives, to the subject.

### Claim 14 (depends on 13)

A method of treating as claimed in claim 13, wherein the additives are extracted from the same fenugreek, which comprises of a group consisting galactomannan.

### Claim 15 (depends on 13)

A method of treating as claimed in claim 13, wherein the diabetes is type II diabetes.

### Claim 16 (depends on 13)

A method of treating as claimed in claim 13, wherein the composition is free of adverse effects.

### Claim 17 (depends on 13)

A method of treating as claimed in claim 13, wherein the administration of the synergistic composition is at dosage ranging between 50 to 2000 mg/kg body weight.

### Claim 18 (depends on 13)

A method of treating as claimed in claim 13, wherein the method shows hypoglycemic effect of about 35%.

### Claim 19 (depends on 13)

A method of treating as claimed in claim 13, wherein the method shows about 300% increase in the viability of the islets.

### Claim 20 (depends on 13)

A method of treating as claimed in claim 13, wherein the method maintains the morphology of the pancreatic cells.

### Claim 21 (depends on 13)

A method of treating as claimed in claim 13, wherein the Trigonelline, amino acids and galactomannan fibers are administered orally.

### Claim 22 (depends on 13)

A method as claimed in claim 13, wherein the Trigonelline, amino acids and galactomannan fibers act at the pancreas through potassium channel mediated insulin secretion.
